Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infrared therapy noncovered

This article was originally published in The Gray Sheet

Executive Summary

More than 4,000 comments from patients and clinicians supporting market-leading Anodyne infrared therapy could not sway CMS to reverse its proposed noncoverage decision for its use to treat peripheral sensory neuropathy, wounds, skin ulcers and related symptoms (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS' final national coverage decision, released Oct. 24, cites lack of evidence of the treatment's durability, poor methodology in studies with positive results, significant placebo effect and concerns about adverse events reported to FDA...

You may also be interested in...

In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request

CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy

Everlywell Raises $175M To Expand Consumer Lab Testing, Digital Health

The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts